Be6A Lung-02: This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Progression Free Survival (PFS) is defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurs first.

Objective response rate is defined as the proportion of participants who have a confirmed CR or PR, as best overall response assessed by BICR as per RECIST 1.1, from the date of randomization to the date of disease progression, death due to any cause, whichever occurs first.

defined as the proportion of participants who achieve a best response of complete response (CR) or partial response (PR) using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria as assessed by Investigator.

Duration of response is defined as the time from first documented evidence of CR or PR until progressive disease (PD) as determined by BICR assessment as per RECIST 1.1 or death due to any cause, whichever occurs first.

defined time from the initial response (CR or PR) until documented tumor progression or death from any cause and based on Investigator assessment.

Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to [study drug] was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

To characterize the pharmacokinetics (PK) of sigvotatug vedotin when administered in combination with pembrolizumab

To characterize the pharmacokinetics (PK) of sigvotatug vedotin when administered in combination with pembrolizumab

To characterize the pharmacokinetics (PK) of sigvotatug vedotin when administered in combination with pembrolizumab

To characterize the pharmacokinetics (PK) of sigvotatug vedotin when administered in combination with pembrolizumab

To characterize the immunogenicity of sigvotatug vedotin when administered in combination with pembrolizumab